Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 200
Avg Vol 1,032
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 65%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. The company offers Dayvigo, an orexin receptor antagonist for the treatment of insomnia; LEQEMBI, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody for Alzheimer's disease; Lenvima, an orally available multiple receptor tyrosine kinase inhibitor for the treatment of thyroid cancer and hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and endometrial ca...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 81 3 3817 3700
Address:
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan
Latest News on ESALF
No data available.